---
title: "SHANGHAI SERUM BIO-TECHNOLOGY's net profit for the year 2024 is 45.3956 million yuan, a year-on-year increase of 17.08%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229536749.md"
description: "SHANGHAI SERUM BIO-TECHNOLOGY released its 2024 annual performance report, with total operating revenue of 195 million yuan, a year-on-year increase of 2.51%; net profit attributable to the parent company's owners was 45.3956 million yuan, a year-on-year increase of 17.08%; net profit excluding non-recurring gains and losses was 29.3550 million yuan, a year-on-year increase of 22.30%; basic earnings per share were 0.42 yuan. The company focuses on its main business, market expansion, increased product sales and output, stable growth in operating revenue, recovery in gross profit margin, and a year-on-year decrease in R&D expenses"
datetime: "2025-02-25T07:40:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229536749.md)
  - [en](https://longbridge.com/en/news/229536749.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229536749.md)
generator: "portal-rs"
---

# SHANGHAI SERUM BIO-TECHNOLOGY's net profit for the year 2024 is 45.3956 million yuan, a year-on-year increase of 17.08%

According to the Zhitong Finance APP, SHANGHAI SERUM BIO-TECHNOLOGY (688163.SH) released its performance report for the year 2024. The company's total operating revenue for 2024 was 195 million yuan, an increase of 2.51% year-on-year; the net profit attributable to the parent company's owners was 45.3956 million yuan, an increase of 17.08% year-on-year; the net profit attributable to the parent company's owners after deducting non-recurring gains and losses was 29.3550 million yuan, an increase of 22.30% year-on-year; the basic earnings per share were 0.42 yuan.

During the reporting period, the company focused on its main business, further expanded the market, increased product sales and production, and achieved steady growth in operating revenue, with a certain degree of recovery in gross profit margin; due to the high base of R&D expenses in the previous year, R&D expenses in this reporting period decreased year-on-year

### Related Stocks

- [688163.CN](https://longbridge.com/en/quote/688163.CN.md)

## Related News & Research

- [12:01 ETNEI Global Relocation Wins Gold Stevie® for Company of the Year in 2026 International Business Awards®](https://longbridge.com/en/news/296515963.md)
- [Idealist Celebrates Thirty Years of Helping People Move From Intention to Action](https://longbridge.com/en/news/296683442.md)
- [Soccerment Group Launches Sics Atlas, the First AI-Native Football Platform for Match Analysis and Scouting](https://longbridge.com/en/news/296495845.md)
- [09:30 ETFirst Mold Returns to Meximold 2026: Enhanced Large‑Part Capacity for North America](https://longbridge.com/en/news/296624448.md)
- [09:03 ETPlayOn Sports Brings the Nation's Top High School Football Games to Fans Nationwide with 2026 MaxPreps Game of the Week](https://longbridge.com/en/news/296621737.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**